Journal of Advances and Scholarly Researches in Allied Education
Vol. 18, Issue No. 1, January-2021, ISSN 2230-7540

A Study on Development and Characterization of Chemicals for Cancer Control

Misfiqua[1]* Dr. Ashiya Fatima[2]

[1] Student

[2] Azteca University

Abstract – Cancer is still one of the major causes of mortality in both developing and developed countries. At present, in spite of intensive interventions, a large number of patients suffer from poor prognosis. Therefore, the effort for finding new anticancer agents with better efficacy and lesser side effects has been continued. This review was focused on the Natural compounds targeting cancer stem cells, Cancer-producing chemical compounds and Compound chemical analysis and target prediction.

Keywords – Cancer, Chemical, Development, Characterization, Cancer Control

----------X----------

INTRODUCTION

Malignancy is considered by general supposition to be an inexorably undermining ailment, influencing individuals, everything being equal. It is the subsequent driving reason for death among the worldwide populace, following cardiovascular maladies (1, 2). Individuals will in general acknowledge disease with emotionlessness and submit to delayed treatment periods that are not generally compelling (2). The word cancer-causing has been characterized as the capacity of a compound to follow up on one of a few organs or tissues to unchain the cycle of malignancy improvement in people and creatures under fitting conditions (3, 4). This definition is presently inadequate, with the revelation of different systems associated with carcinogenesis (5). A compound is viewed as cancer-causing from an exploratory perspective when its organization to research facility creatures initiates a factually critical increment in the frequency of at least one histological sorts of neoplasia contrasted with creatures not presented to the substance in the benchmark group (6).

CANCER

One of the most predominant reasons for ailment related passings overall is disease, known as the unusual division, expansion and aggregation of cells in a life form. Just as spreading to removed organs, it can influence a solitary organ (24). Since cell division and development are constrained by qualities, disease is fundamentally a quality related sickness. The qualities on the chromosomes are firmly pressed, and the cell's capacity can be straightforwardly influenced by physical or chemical changes in these qualities. In spite of the fact that DNA fix frameworks in case of harm can improve the capacity of the quality, they can not generally be fruitful. For this situation, the deficient or inaccurate creation of proteins as quality items prompts cell utilitarian disturbance. Epigenetic adjustments, for example, methylation, acetylation, phosphorylation and ribosylation, which modify the quality 's work without changing its structure, are another factor that influences the quality 's work. These changes are fit for acting just on a specific site, yet may likewise prompt local erasures, additions or inversions influencing all or a huge aspect of the chromosomes (7-9).

In malignant growth formation, there are three quality gatherings that assume a critical job: oncogenes (qualities, for example, RAS, Erk and MYC), qualities that smother tumors (TP53 quality) and qualities that fix DNA. Proto-oncogenes can be dynamic and transform into oncogenes because of changes, expanded quality articulation, quality duplications and/or chromosomal modifications, which are ordinary qualities that permit cell development and separation. In case of harm, tumor silencer qualities control cell division and multiplication, start DNA fix and trigger apoptosis if the endeavor at fix tumbles down. Erasures, point changes, quieting of the epigenetic quality, inappropriate chromosome division and mitotic recombinations can prompt loss of tumor silencer quality control, bringing about cell cycle loss of control and carcinogenesis. DNA fix qualities that draw in the vital proteins to the site of harmed DNA, in this manner reestablishing the quality's

work, are another significant gathering of qualities. Another significant capacity of DNA fix qualities is the annihilation of the apoptotic or necrotic cell pathway in case of insufficient fix. In any case, loss of capacity in this critical quality gathering is a typical issue in the formation of cell disease. The Breast Cancer (BRCA) quality, which causes bosom malignant growth in light of impeded capacity, is one of the most perceived DNA fix qualities (8, 9).

CANCER TREATMENT

Albeit some malignant growth treatment standards have been set up, various methodologies and therapies are utilized explicitly for each kind of disease. In malignant growth treatment alone or in mix, organic treatments, for example, radiotherapy, chemotherapy, medical procedure, immunotherapy, hormone treatment, directed treatment and quality treatment might be utilized (10, 11). In any case, there are preferences just as disservices to these strategies, known as the best quality level. Extreme symptoms of these medications on the hematopoietic framework, bone marrow and gastrointestinal epithelial cells and hair follicles are a significant weakness (31-34) in spite of the revelation of numerous chemotherapeutic medications (Adriamycin, Cisplatin, Campotins, Vinblastin, Mercaptopurine, and so on) that hinder uncontrolled cell division measure for the therapy of different malignancy types(12, 13). What's more , multi-drug opposition (MDR) is another critical anticancer therapy issue (14). Numerous investigations are being directed to find and create compelling anticancer medications because of issues, for example, cytotoxicity and medication obstruction in existing chemotherapeutic specialists. Past examinations have indicated that numerous compounds got from common assets might be utilized in malignant growth treatment as preventive and restorative operators. In mix with chemotherapy or alone in various kinds of cancers, these compounds have been appeared to expand the viability and resistance of chemotherapeutic specialists (15-22)

CANCER STEM CELLS (CSCS)

Immature microorganisms of malignancy (CSCs) are fundamentally the same as expected undifferentiated organisms, especially as a result of their capacity to offer ascent to a wide range of cells in a specific disease. In addition, CSCs share a few properties with ordinary undifferentiated organisms, including film transport, DNA fix, self-recharging control capacity, and separation in light of oncogenic and outer incitement transformations. In any case, there are some particular highlights, for example spheroid formation in culture, articulation of explicit marker proteins (aldehyde dehydrogenase; ALDH, separation bunch 133; CD133, separation group 44; CD 44, and so on), multi-drug obstruction protein articulation and hostile to apoptotic protein articulation. This subpopulation of cells may emerge through dedifferentiation from common foundational microorganisms or ancestor cells, fat determined stromal cells or even separated cells. CSCs are found in hematological cancers and are exceptionally impacted by the tumor microenvironment in numerous strong tumors, including melanoma, osteosarcoma, prostate, ovarian, gastric, glioblastoma, and their tumorigenic limit. What's more, heterogeneity is another indispensable element of CSCs, which has prompted more troubles in planning treatment against these unmistakable tumor populace aggregates (23). Likewise, versatility offers a powerful limit through which cells can change to a CSC state from a non-CSC state and the other way around. Through explicit microenvironmental signals and cell communications emerging from the tumor specialty, disease cells gain this capacity (24).

NATURAL COMPOUNDS TARGETING CANCER STEM CELLS

Customary malignant growth treatments, for example, chemotherapy and radiation treatment neglect to target undifferentiated organisms of disease and, also, harmfulness to ordinary cells is brought about by vague treatments. Strikingly, both in vivo and in vitro, numerous normal compounds have just shown enemy of CSC properties (25). The outcomes demonstrated that characteristic compounds may can possibly actuate CSC passing. Also, regular compounds could sharpen them to customary treatments, forcing them to re-separate or keep them from entering a lethargic or safe state, with the possibility to improve the administration of disease in clinical settings (25). The parts of normal compounds against CSCs in various cancers are delineated in the accompanying areas.

ANTI-CANCER CHEMICAL COMPOUNDS

Against tumor chemical compound screening in vivo is helpful in that the cycle can distinguish compounds that viably stifle tumors without genuine results. In vivo screening, in any case, is intricate and tedious dependent on measures that assess tumorigenicity or metastasis of disease cells in mice. We built up a test dependent on early stage improvement to beat such issues, which imparts organic attributes to malignancy tissues.

Cells that start from epithelial cells cause EMT in vertebrate incipient organisms during early turn of events (for example gastrulation and relocation of neural peak cells [NCC]) and become exceptionally obtrusive. They regularly, as a gathering of cells, move and attack. Malignancy cells attack the stromal tissues and vessels along with EMT to set up metastatic settlements in numerous cancers (26-28). Hence, to recognize compounds that restrain disease intrusion and metastasis, we

utilized frog undeveloped organisms. Since they grow rapidly and the cell practices of gastrulation and NCC are surely known, we picked frog undeveloped organisms (29). The Xenopus framework can add to the understanding of pathogenesis and tumor science. In spite of the fact that the essential amino corrosive successions of frog atoms contrast from those in warm blooded animals, numerous mammalian builds display useful homology, and chemical compounds, for example, the MEK inhibitor U0126 influence the capacity of MEK in both frog and mammalian cells.

CANCER-PRODUCING CHEMICAL COMPOUNDS

The degree of importance which is attached to the carcinogenic substances depends upon whether such compounds are concerned in the etiology of 'spontaneous' human cancer. Perhaps closely bound up with this question is another unsolved problem of outstanding importance, namely, the manner in which these compounds bring about a transformation of normal cells into malignant cells. At least until answers are forthcoming to these questions, the carcinogenic compounds will continue to furnish useful material for the experimental study of cancer. Industrial cancer, in its various forms, has stimulated the researches which have brought to light the cancer-producing properties of the various carcinogenic agents, and in the preparation of the present brief survey of these agents regard has been paid to the correlation of the various forms of industrial cancer with their causative compounds. In the earlier work on the carcinogenic properties of substances the skin of the mouse was usually employed as the test object. This was due to a number of reasons. Results could be expected comparatively rapidly; the ear of the rabbit, which had been first used, was less satisfactory in this respect. Moreover, the modes of application of the substances under examination were considerably restricted by the toxic and inflammatory properties of the crude mixtures which it was necessary to use. Many of these difficulties have been resolved by the availability of pure chemical compounds of high carcinogenic potency, and in recent years new techniques of admini: 'Tation have been developed, so that malignant tumours have been induced in a large number of different tissues, and in several different species. One outcome of these and other studies has been the revelation that, in certain strains of animal, tumours of a particular organ are apt to occur spontaneously. Thus, some strains of mice show a high incidence of mammary carcinoma ; other strains show a high incidence of lung cancer ; and there is at least one strain of mice in which livercell cancer (hepatoma) is apt to arise spontaneously. These findings indicate the caution that must be used in interpreting the results when cancers of such organs are found in experimental animals, especially when the tumours arise at sites other than that of application of the carcinogenic agent. Yet even so, tumours clearly attributable to the treatment have been found, usually at the site of application, in a variety of tissues of animals treated with carcinogenic compounds. In this respect the most versatile substances so far found are contained in the group of polycyclic hydrocarbons, mostly related to I : 2-benzanthracene (I), in which substituents are present at certain welldefined positions in the molecule. With these compounds malignant tumours have been obtained, usually in mice and rats, in such tissues as the skin, the subcutaneous tissues, the peritoneal cavity, the liver, the prostate, the forestomach, the brain, and the spleen ; and this list is not exhaustive. Less widespread in their effect are members of other classes of compounds, where usually carcinogenic action has not been shown except in a single organ. In this connexion it needs to be borne in mind that these substances have not usually been so widely investigated as the polycyclic hydrocarbon class. The earliest form of industrial cancer, recognized as such in the latter part of the eighteenth century, was the cancer of the scrotum to which chimney sweeps were especially liable. This was caused by soot, and the pursuit of the clue so provided culminated eventually in the isolation from coal tar of the individual compound responsible. This is 3:4-benzpyrene (n), an aromatic hydrocarbon, the relationship of which to I : 2-benzanthracene (I) is apparent from the formulre. 3: 4-Benzpyrene is undoubtedly the principal cancer-producing constituent of coal tar. It has a high boiling point, and hence is present to an appreciable extent only in the highest boiling fractions of the tar. There are grounds for inferring that this or a similar compound is responsible for the carcinogenic properties shown to varying degrees by some of the mineral lubricating oils. Prolonged contact with industrial products of these types is now recognized as being fraught with danger, and the use of suitable precautions should lead to diminution if not to eradication of the form of industrial cancer which they are liable to cause. The widespread use of tar in road surfaces, and the publication of statistics which appear to show that cancer of the lung is increasing at an alarming rate, have led to the suggestion that tarred road dust may be partly responsible for this increase. This suggestion has been tested experimentally; but although an increase in lung cancer was found in mice breathing air impregnated with road dust, this increase was not wholly related to the presence of tar in the dust, and the results of the experiments do not directly implicate such an agent in the increase of the human disease. Furthermore, it is considered by many authorities that the recorded increase in lung cancer is largely accounted for by improved methods of diagnosis. Unconvincing attempts have also been made to implicate pollution of town air by soot, exhaust fumes, etc., and also tobacco smoking in the increase of lung cancer. However, the knowledge that the agencies in question may be, and

sometimes are, associated with carcinogenic substances, does not allow such speculations to be too lightly dismissed.



(I)



(II)

- **Cholanthrene Derivatives**

By virtue of their chemical relationship with the cholane (bile corrosive) class of normally happening substances, the cancer-causing compounds of the cholanthrene bunch merit separate thought. They are, nonetheless, basically of similar kind as subordinates of benzanthracene.

Wieland and Dane (29) and Cook and Haslewood (31) autonomously arranged methylcholanthrene by dehydrogenation of dehydronorcholene, a pentacyclic hydrocarbon got by Wieland and Schlichting in 1925 (30) from bile corrosive, deoxycholic corrosive, by basic chemical transformations. Methylcholanthrene's atomic structure was shown by its debasement by Cook and Haslewood (32) to 5:6-dimethyl-1:2-benzanthraquinone, indistinguishable from an artificially arranged example by a strategy that set up its constitution. Fieser and Seligman's (33) union of methylcholanthrene is in finished amicability with this structure, and Fieser and Newman have revealed the change of cholic corrosive into methylcholanthrene (34). The two fundamental acids of human bile are cholic corrosive and deoxycholic corrosive, so that in these responses we have a nearly basic chemical change of significant constituents of the human body into disease delivering hydrocarbons connected to those definitely known in structure. No further accentuation is required on the estimation of these connections. Until this point, there has been no proof that the creation of methylcholanthrene or a related compound in the body is an etiological factor in human malignant growth.

In London and at Harvard, the parent pentacyclic fragrant hydrocarbon, cholanthrene, has additionally been combined. The natural testing of cholanthrene and methylcholanthrene has indicated that these two hydrocarbons are more impressive cancer-causing specialists than any recently explored compounds. Epitheliomas are delivered when painted on the skin of mice in 0.3% benzene arrangement, the primary tumors showing up after a normal time of 70 to 80 days; sarcomas are created when subcutaneously infused into rodents and mice (results with mice have just been accounted for with cholanthrene). Cholanthrene is instigated by tumors over a moderately brief timeframe, and the methyl gathering of methyl-cholanthrene seems, by all accounts, to be of little hugeness in deciding its cancer-causing potential. The pentacyclic framework in the atom is the principle auxiliary trademark.

- **Epidermal growth factor receptor (EGFR)**

An individual from the ErbB receptor family, the epidermal development factor receptor is communicated in typical human cells, yet essentially more elevated levels of receptor articulation have been appeared to relate with danger identified in an assortment of epithelial cancers. Cetuximab is a human-murine mAb illusory that ties seriously with a high EGFR liking, making it a potential anticancer treatment target. Cetuximab has been appeared to explicitly and successfully target gold nanoparticles in vitro to EGFR-positive pancreatic and colorectal carcinoma cell lines. Ensuing presentation of the focused on cells to non-ionizing radiofrequency energy has brought about the gold nanoparticles producing heat, bringing about the dangerous cells being thermally removed.

In a pancreatic adenocarcinoma xenograft murine model, Glazer et al. (2010) investigated cetuximab-focused on gold nanoparticles. Radiofrequency presentation of tumor xenografts after intraperitoneal infusion of cetuximab-formed gold nanoparticles brought about radiofrequency field-initiated pulverization of xenografts of pancreatic carcinoma without proof of solid organ injury.

Regardless of targeting gold nanoparticles for healing purposes, Cetuximab has been inspected for its capacity to target gold nanoparticles for threatening development ID. Puvanakrishnan et al. (2012) have indicated that effective use of gold nanorods explicitly focused to EGFR brings about an altogether more prominent picture contrast contrasted with nontargeted gold nanorods for skin surface developing disease. These outcomes exhibit the chance of utilizing restricted band close infrared imaging to picture and delineate tumor edges following effective organization of focused gold nanorods during careful resection. Yang et al. (1995) recommended that for in situ identification of live malignancy cells, cetuximab-formed gold nanoparticles could be utilized. In examination with EGFR-lacking MCF7 cells, the EGFR-focused on nanoprobes had the option to distinguish EGFR-positive A431 cells with multiple times more prominent particularity and affectability.

Powerful targeting of superparamagnetic iron oxide nanoparticles, amazing differentiation specialists in

MRI, has been appeared to overexpress EGFR cells.

COMPOUND CHEMICAL ANALYSIS AND TARGET PREDICTION:

We broke down the chemical structures of the top compounds of each stage utilizing our recently evolved Chemical Similarity Network Analysis Pulldown (CSNAP) computational program to understand the physiochemical properties of compounds inside every cell cycle class. In the ChEMBL information base, CSNAP looked for compounds that share chemical likeness to hit compounds, recovered the bioactivity information of each compound found in the ChEMBL information base and composed these compounds into network similitude charts that share normal chemotypes. To score target tasks by including the objective explanation recurrence in the nearest neighborhood of question compounds, an executed scoring capacity (S-score) was utilized. On heatmaps (scaled from 0 to 1), the anticipated compound on/off targets spoke to by the S-score were imagined and the most conspicuous focuses from the top pinnacles were chosen, which connected with the combined S-score ('S-Score) of each alloted focus in the objective range. Beforehand, this methodology has empowered us to effectively distinguish key medication focuses for M-stage compounds, including tubulin targeting compounds and novel ligands not recently explained in bioactivity information bases. In the CSNAP examination of 69 G1 inhibitors, 148 S inhibitors and 7 G2 inhibitors, 64 G1 chemotypes, 68 S chemotypes and 5 G2 chemotypes were distinguished, separately (35).

CONCLUSION:

The study on natural compounds targeting cancer stem cells, Cancer-producing chemical compounds and Compound chemical analysis and target prediction concludes that Cancer cell proliferation relies on the ability of cancer cells to grow, transition through the cell cycle, and divide. To identify novel chemical probes for dissecting the mechanisms governing cell cycle progression and cell division, and for developing new anticancer therapeutics, we developed and performed a novel cancer cell-based high-throughput chemical screen for cell cycle modulators.

REFERENCES:

1. HUFF J. (1992). Chemical toxicity and chemical carcinogenesis. Is there a causal connection? A comparative morphological evaluation of 1500 experiments. IARC Sci Pub 116: pp. 437–475.

2. WEISBURGER JH (1999). Carcinogenicity and mutagenicity testing, then and now. Mutat Res 437: pp. 105–112.

3. GOMES-CARNEIRO MR, RIBEIRO-PINTO LF AND PAUMGARTTEN FJ (1997). Environmental risk factors for gastric cancer: the toxicologist's standpoint. Cad Saúde Pública 13 (Suppl): pp. 27–38.

4. HUFF J. (1999). Chemicals associated with tumours of the kidney, urinary bladder and thyroid gland in laboratory rodents from 2000 US National Toxicology Program / National Cancer Institute bioassays for carcinogenicity. IARC Sci. Pub 147: pp. 211–225.

5. Butterworth BE AND Bogdanffy MS (1999). A comprehensive approach for integration of toxicity and cancer risk assessments. Regul Toxicol Pharmacol 29: pp. 23–36.

6. Gutiérrez JB and Salsamendi AL (2001). Fundamientos de ciência toxicológica. Diaz de Santos, Madrid, pp. 155–177.

7. Cohen, S.M.; Ellwein, L.B. (1991). Genetic errors, cell proliferation, and carcinogenesis. Cancer Res. 1991, 51, pp. 6493–6505.

8. Blackadar, C.B. (2016). Historical review of the causes of cancer. World J. Clin. Oncol. 2016, 7, pp. 54–86. [CrossRef]

9. Siegel, R.L.; Miller, K.D.; Jemal, A. (2015). Cancer statistics, 2015 CA Cancer J. Clin., 65, pp. 5–29.

10. Fitzmaurice, C.; Dicker, D.; Pain, A.; Hamavid, H.; Moradi-Lakeh, M.; MacIntyre, M.F.; Allen, C.; Hansen, G.; Woodbrook, R.; Wolfe, C.; et. al. (2015). Global Burden of Disease Cancer Collaboration, The Global Burden of Cancer 2013. JAMA Oncol. 2015, 1, pp. 505–527. [PubMed]

11. Pavlopoulou, A.; Spandidos, D.A.; Michalopoulos, I. (2015). Human cancer databases (review). Oncol. Rep., 33, pp. 3–18. [CrossRef] [PubMed]

12. Khoobi, M.; Foroumadi, A.; Emami, S.; Safavi, M.; Dehghan, G.; Alizadeh, B.; Ramzani, A.; Ardastani, S.; Shafiee, A. (2018). Coumarin based bioactive compounds: Facile synthesis and biological evaluation of coumarin-fused 1,4-Thiazepines. Chem. Bio. Drug Des., 78, pp. 580–586. [CrossRef] [PubMed]

13. Carter, S.K.; Bakowski, M.T.; Hellman, K. (1989). Chemotherapy of Cancer, 3rd ed.; Wiley & Sons: New York, UY, USA.

14. Sandhu, S.; Bansal, Y.; Silakari, O.; Bansal, G. (2014). Coumarin hybrids as novel therapeutic agents. Bioorg. Med. Chem. 2014, 22, pp. 3806–3814. [CrossRef]

15. Mann, J. (2002). Natural products in cancer chemotherapy: Past, present and future. Nat. Rev. Can., 2, pp. 143–148. [CrossRef]

16. Farabegoli, F.; Papi, A.; Bartolini, G.; Ostan, R.; Orlandi, M. (2010). (-)-Epigallocatechin-3-gallate downregulates Pg-P and BCRP in a tamoxifen resistant MCF-7 cell line. Phytomedicine, 17, pp. 356–362. [CrossRef] [PubMed]

17. Nautiyal, J.; Banerjee, S.; Kanwar, S.S.; Yu, Y.; Patel, B.B.; Sarkar, F.H.; Majumdar, A.P. (2011). Curcumin enhances dasatinib-induced inhibition of growth and transformation of colon cancer cells. Int. J. Cance, 128, pp. 951–961. [CrossRef] [PubMed]

18. Sen, S.; Sharma, H.; Singh, N. (2005). Curcumin enhances Vinorelbine mediated apoptosis in NSCLC cells by the mitochondrial pathway. Biochem. Biophys. Res. Commun., 331, pp. 1245–1252. [CrossRef] [PubMed]

19. Wang, C.Z.; Yuan, C.S. (2008). Potential role of ginseng in the treatment of colorectal cancer. Am. J. Chin. Med., 36, pp. 1019–1028. [CrossRef] [PubMed]

20. Banerjee, S.; Kambhampati, S.; Haque, I.; Banerjee, S.K. (2011). Pomegranate sensitizes Tamoxifen action in ER-α positive breast cancer cells. J. Cell Commun. Signal., 5, pp. 317–324. [CrossRef] [PubMed]

21. Ishii, T.; Teramoto, S.; Matsuse, T. (2004). GSTP1 affects chemoresistance against camptothecin in human lung adenocarcinoma cells. CancerLett., 216, pp. 89–102. [CrossRef]

22. Batlle, E.; Clevers, H. (2017). Cancer stem cells revisited. Nat Med,, 23(10), pp. 1124-1134.

23. Moghbeli, M.; Moghbeli, F.; Forghanifard, M.M. Abbaszadegan MR (2014). Cancer stem cell detection and isolation. Med. Oncol., 31(9), pp. 69

24. Dontu, G.; Abdallah, W.M.; Foley, J.M.; Jackson, K.W.; Clarke, M.F.; Kawamura MJ.; Wicha, M.S. (2003). In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes. Dev., 17(10), pp. 1253-70.

25. Oikonomou, E.; Anastasiou, M.; Siasos, G.; Androulakis, E.; Psyrri, A.; Toutouzas, K.; Tousoulis, D. (2018). Cancer Therapeutics-Related Cardiovascular Complications. Mechanisms, Diagnosis and Treatment. Curr. Pharm. Des., 24(37), pp. 4424-4435.

26. Friedl P, Hegerfeldt Y, Tusch M. (2004). Collective cell migration in morphogenesis and cancer. Int J Dev Biol.; 48: pp. 441–9. [PubMed] [Google Scholar]

27. Wolf K, Wu YI, Liu Y et. al. (2007). Multi-step pericellular proteolysis controls the transition from individual to collective cancer cell invasion. Nat Cell Biol.; 9: pp. 893–904. [PubMed] [Google Scholar]

28. Friedl P, Gilmour D. (2009). Collective cell migration in morphogenesis, regeneration and cancer. Nat Rev Mol. Cell Biol.; 10: pp. 445–57. [PubMed] [Google Scholar]

29. WIELAND, H., AND DANE, E. (1933). Ztschr. f. physiol. Chem. 219: pp. 240.

30. WIELAND, H., AND SCHLICHTING, O. (1925). Ztschr. f. physiol. Chem. 150: pp. 273.

31. COOK, J. W., AND HASLEWOOD, G. A. D. (1933). Chem. & Indust. 38: 758, pp. 1933.

32. COOK, J. W., AND HASLEWOOD, G.A. D. (1934). J. Chem. SOC., p. 428.

33. FIESER, L. F., AND SELIGMAN, A. M. (1935). J. Am. Chem. SOC. 57: pp. 942.

34. FIESER, L. F., AND NEWMAN, M. S. (1935). J. Am. Chem. SOC. 57: pp. 961.

35. COOK, J. W., HASLEWOOD, G. A. D., AND ROBINSON, A. M. (1935). J. Chem. SOC., p. 667.

Corresponding Author

Misfiqua*

Student